$0.88
7.92% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
US60855D1019
Symbol
MBRX
Sector
Industry

Moleculin Biotech, Inc. Stock price

$0.96
-0.19 16.43% 1M
-1.56 61.87% 6M
-0.74 43.47% YTD
-4.49 82.37% 1Y
-27.99 96.68% 3Y
-50.29 98.12% 5Y
-719.04 99.87% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.00 0.20%
ISIN
US60855D1019
Symbol
MBRX
Sector
Industry

Key metrics

Market capitalization $13.45m
Enterprise Value $9.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-26.64m
Free Cash Flow (TTM) Free Cash Flow $-23.88m
Cash position $4.28m
EPS (TTM) EPS $-7.12
P/E forward negative
Short interest 9.08%
Show more

Is Moleculin Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Moleculin Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Moleculin Biotech, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Moleculin Biotech, Inc. forecast:

Buy
100%

Financial data from Moleculin Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
46% 46%
-
-0.13 -0.13
46% 46%
-
- Selling and Administrative Expenses 8.66 8.66
10% 10%
-
- Research and Development Expense 18 18
9% 9%
-
-27 -27
10% 10%
-
- Depreciation and Amortization 0.13 0.13
46% 46%
-
EBIT (Operating Income) EBIT -27 -27
10% 10%
-
Net Profit -22 -22
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Moleculin Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moleculin Biotech, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in ...
Neutral
Seeking Alpha
10 days ago
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference Call Participants Jonathan Aschoff - Roth Capital Partners Jason McCarthy - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Hello, and welcome to the Moleculin Biote...
Neutral
GlobeNewsWire
10 days ago
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025
More Moleculin Biotech, Inc. News

Company Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Head office United States
CEO Walter Klemp
Employees 17
Founded 2015
Website www.moleculin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today